AXIN2 Gene Mutation Analysis
Axin-2, is an 843 amino acid protein localized in the cytoplasm, nucleus and mitotic spindle. It is encoded by the AXIN2 gene and plays an important role in the regulation of the stability of beta-catenin in the Wnt signaling pathway. The AXIN2 gene has been mapped to 17q23-q24, a region that shows frequent loss of heterozygosity in breast cancer, neuroblastoma, and other tumors. Axin-2 acts as a tumor suppressor and the deregulation of beta-catenin is an important event in the genesis of a number of malignancies. Mutations in this gene have been associated with colorectal cancer with defective mismatch repair and liver tumors.
AXIN2 gene polymorphic variants may be associated with both hypodontia and oligodontia (characterized by the lack of six or more permanent teeth). In early life, mutation seems to disrupt tooth development and later contributes to the emergence of polyps and eventually colon cancer. The lack of permanent teeth may be an indicator of colon cancer susceptibility.
AXIN2 gene mutation analysis may be tested as part of a cancer panel such as the hereditary gastrointestinal cancer panel, or the hereditary neurologic cancer panel by next generation sequencing.
- As an aid in diagnosis and management of hereditary colon cancer
- As aid in diagnosis and management of gastrointestinal cancers
- As an aid in diagnosis and management of neuroblastoma and other central nerve system cancers
- Useful to find the cause of familial tooth agenesis and a predisposition to colorectal cancer
Positive:
- Mutation of AXIN2 gene in autosomal dominant oligodontia-colorectal cancer syndrome, colorectal cancer, hepatocellular carcinoma, ovarian endometrioid adenocarcinoma, hepatoblastomas
- AXIN2 gene mutation in the carrier
Negative:
- No change in the gene or not a carrier of AXIN2 gene mutation
Negative for mutations analyzed (No potential pathogenic variant detected)
Whole blood (Lavender top tube)
Stability
- Ambient: 72 hours
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Oncotarget. 2016 Apr 19;7(16):21840-52. [PMID: 27009842]
- Oncotarget. 2017 Mar 14;8(11):18444-18455. [PMID: 28055978]
- BDJ Open. 2019;5: 13. [PMID: 31632692]
- Am J Med Genet A. 2018;176: 1976-80. [PMID: 30088857]
- Neuro Endocrinol Lett. 2017;38: 131-37. [PMID: 28759178]
- Eur J Oral Sci. 2016;124: 228-33. [PMID: 27090353]
- Cancer Cell Int. 2015;15: 68. [PMID: 26161041]
- Cancer Lett. 2014; 355: 1-8. [PMID: 25236910]
- J Biol Chem. 2002;277: 21657-65. [PMID: 11940574]